Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 December 2023

doi:10.20944/preprints202311.0501.v2

Disclaimer/Publisher’s Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) andcontributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting
from any ideas, methods, instructions, or products referred to in the content.

Communication

Cx1Mab-1: A Novel Anti-Mouse CXCR1 Monoclonal
Antibody for Flow Cytometry
Guanjie Li 1,†, Tomohiro Tanaka 1,†, Tsunenori Ouchida 1, Mika K. Kaneko 1, Hiroyuki Suzuki 1,*
and Yukinari Kato 1,*
Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryomachi, Aoba-ku, Sendai 980-8575, Miyagi, Japan.
* Correspondence: hiroyuki.suzuki.b4@tohoku.ac.jp (H. S.); yukinari.kato.e6@tohoku.ac.jp (Y.K.); Tel.: +8122-717-8207 (H.S., Y.K.)† Contributed equally to this work.
1

Abstract: The C-X-C motif chemokine receptor-1 (CXCR1) is a rhodopsin-like G-protein-coupled receptor,
expressed on the cell surface of immune cells and tumors. CXCR1 interacts with some C-X-C chemokines, suchas CXCL6, CXCL7, and CXCL8/interleukin-8, which are produced by various cells. Since CXCR1 is involved inseveral diseases including tumors and diabetes mellitus, drugs targeting CXCR1 has been developed.
Therefore, the development of sensitive monoclonal antibodies (mAbs) for CXCR1 has been desired for the
diagnosis and treatment. This study established a novel anti-mouse CXCR1 (mCXCR1) mAb; Cx1Mab-1 (rat
IgG1, kappa), using the Cell-Based Immunization and Screening (CBIS) method. Cx1Mab-1 reacted with
mCXCR1-overexpressed Chinese hamster ovary-K1 (CHO/mCXCR1) and mCXCR1-overexpressed LN229
glioblastoma (LN229/mCXCR1) in flow cytometry. Cx1Mab-1 demonstrated a high binding affinity for
CHO/mCXCR1 and LN229/mCXCR1 with a dissociation constant of 2.6×10-9 M and 2.1×10-8 M, respectively.
Furthermore, Cx1Mab-1 could detect mCXCR1 by western blot analysis. These results indicated that Cx1Mab1 is useful for detecting mCXCR1, and provides a possibility for targeting mCXCR1-expressing cells in vivo
experiments.

Keywords: mouse CXCR1; CBIS method; monoclonal antibody; flow cytometry

1. Introduction
Chemokines can be classified into four different subfamilies: C-C, C-X-C, C-X3-C, and X-C,
depending on the number and position of cysteine residues in their N-terminus. C-X-C means thefirst two cysteine amino acids are divided by other amino acids. Chemokines play pivotal roles in
immune responses, such as infiltration and migration of immune cells by binding to its cognate
receptors [1–3].
The C-X-C motif chemokine receptor 1 (CXCR1), also referred to as C-X-C motif chemokine 8(CXCL8) receptor/interleukin-8 (IL-8) receptor alpha, is one of the G-protein coupled receptors(GPCRs) composed of 350 amino acids with structural seven transmembrane domains [4]. CXCL6
and CXCL7 are also the chemokine ligands of CXCR1 [5]. At the nearly same time that CXCR1 wasdiscovered, the C-X-C motif chemokine receptor 2 (CXCR2), a receptor for CXCL6, CXCL7, and IL-8,
was also identified [6–8]. CXCR2 is also a receptor for CXCL2 and CXCL3 and has 77% amino acids
homology with CXCR1 [9]. Various cells express CXCR1/CXCR2 on the cell surface, including
macrophages, neutrophils, basophils, natural killer cells, mast cells, and other leukocytes [10,11].
Furthermore, CXCR1/CXCR2 expression has also been confirmed in non-immune cells, such as
endothelial cells, fibroblasts, and tumor cells [5,12]. Due to their homology and ligand overlapping,
the functions of CXCR1/CXCR2 have been clarified in many diseases [13].
The IL-8 plays a pivotal role in the tumor microenvironment (TME) as a factor of
immunosuppressive cells’ recruitment, angiogenesis, and induction of epithelial to mesenchymaltransition (EMT) [4]. Functional heterogeneity of cancer-associated fibroblasts (CAFs) is regulated by
IL-8 and other CXCR1/2 ligands [14]. The normal ovarian fibroblast is converted to CAFs by IL-8 and© 2023 by the author(s). Distributed under a Creative Commons CC BY license.

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 December 2023

doi:10.20944/preprints202311.0501.v2

2

triggers tumor growth in mice. Aberrant CXCR1/2 ligands expression in CAFs is closely related togastric cancer progression and poor prognosis in patients [15]. In TME of glioma, IL-8+CD4+ T cells
function in a complex manner with other IL-8-producing cells to govern the immunosuppressive
properties [16]. IL-8 expression is positively correlated with CXCR1/2 and might be a predictive
marker of poor prognosis in glioma, metastatic urothelial carcinoma, and metastatic renal cell
carcinoma patients [17,18]. Furthermore, the blockade of the IL-8-CXCR1/2 axis enhances the antiprogrammed cell death-1 (PD-1) therapeutic effects on glioma [19]. Thus, CXCR1/2 molecules arepromising novel cancer therapeutic targets for tumors [20]. Reparixin, a non-competitive allostericinhibitor of CXCR1/2, could prevent polymorphonuclear cell recruitment [21]. A phase II clinical trial
using navarixin (SCH-527123), a selective CXCR1/2 antagonist, has been conducted in combination
with anti-PD-1 mAb, pembrolizumab, in advanced solid tumors [22,23]. Navarixin blocks neutrophil
recruitment and suppresses the tumor cell growth in a murine melanoma model. CXCR1/2 are
attractive targets for treatment against multiple cancers.
The CXCR1/2 and their chemokine ligands regulate the immune system, which mediates the
progression of diseases such as cancer. Therefore, CXCR1/2 targeting antibodies will contribute to
the diagnosis and therapy. Using the Cell-Based Immunization and Screening (CBIS) method, we
have developed many monoclonal antibodies (mAbs) against C-C chemokine receptors, including
anti-mouse CCR3 [24], anti-mouse CCR8 [25–27], and anti-human CCR9 [28] mAbs. Next, we havebeen trying to establish the anti-C-X-C motif chemokine receptor mAbs. We recently obtained ananti-mouse CXCR3 mAb [29], an anti-mouse CXCR4 mAb [30], an anti-mouse CXCR6 mAb [31]. In
this study, we have successfully developed anti-mouse CXCR1 (mCXCR1) mAbs using the CBIS
method which is applicable to flow cytometry and western blot analysis.
2. Materials and Methods
2.1. Cell lines
LN229, Chinese hamster ovary (CHO)-K1, and P3X63Ag8U.1 (P3U1) cells were obtained fromthe American Type Culture Collection (Manassas, VA). pCMV6neo-myc-DDK vector with mCXCR1(Accession No.: NM_178241) was purchased from OriGene Technologies, Inc. (Rockville, MD). The
plasmid was transfected into the cell lines using a Neon transfection system (Thermo Fisher Scientific,
Inc., Waltham, MA). Subsequently, LN229 and CHO-K1, which stably overexpressed mCXCR1 with
C-terminal myc-DDK tags (hereinafter described as LN229/mCXCR1 and CHO/mCXCR1,
respectively) were established using a cell sorter (SH800; Sony Corp., Tokyo, Japan), following
cultivation in a medium containing 0.5 mg/mL G418 (Nacalai Tesque, Inc., Kyoto, Japan).
CHO-K1, P3U1, and CHO/mCXCR1 were also cultured in a Roswell Park Memorial Institute(RPMI) 1640 medium (Nacalai Tesque, Inc.) that was supplemented with 10% heat-inactivated fetal
bovine serum (FBS, Thermo Fisher Scientific Inc.), 100 units/mL penicillin, 100 μg/mL streptomycin,
and 0.25 μg/mL amphotericin B (Nacalai Tesque, Inc.). LN229 and LN229/mCXCR1 were cultured ina Dulbecco’s Modified Eagle Medium (DMEM) (Nacalai Tesque, Inc.) that was supplemented with
10% heat-inactivated FBS (Thermo Fisher Scientific Inc.), 100 units/mL penicillin, 100 μg/mL
streptomycin, and 0.25 μg/mL amphotericin B (Nacalai Tesque, Inc.). Then, cells were grown in ahumidified incubator, which was supplied with 5% CO2 and 95% air at 37°C.
2.2. Antibodies
The anti-mouse CXCR1/IL-8RA mAb (clone 1122A) was purchased from R&D Systems Inc.
(Minneapolis, MN). An anti-DYKDDDDK mAb (clone 1E6) and an anti-β-actin mAb (clone AC-15)
were purchased from FUJIFILM Wako Pure Chemical Corporation (Osaka, Japan) and Sigma-AldrichCorp. (St. Louis, MO), respectively. The secondary Alexa Fluor 488-conjugated anti-rat IgG and Alexa
Fluor 488-conjugated anti-rabbit IgG were purchased from Cell Signaling Technology, Inc. (Danvers,MA).
2.3. Production of hybridomas

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 December 2023

doi:10.20944/preprints202311.0501.v2

3

For developing anti-mCXCR1 mAbs, a six-week-old female Sprague-Dawley rat (CLEA Japan,
Tokyo, Japan) was immunized intraperitoneally with 1 × 109 cells of LN229/mCXCR1. The
immunogen was harvested after brief exposure to 1 mM ethylenediaminetetraacetic acid (EDTA;
Nacalai Tesque, Inc.). We added Alhydrogel adjuvant 2% (InvivoGen, San Diego, CA) as an adjuvant
in the first immunization. Three additional injections of 1 × 109 cells of LN229/mCXCR1 were
performed without an adjuvant every week. We performed a final booster immunization of 1 × 109
cells of LN229/mCXCR1 intraperitoneally two days before harvesting splenocytes. We fused theharvested splenocytes with P3U1 cells using polyethylene glycol 1500 (PEG1500; Roche Diagnostics,
Indianapolis, IN). Hybridoma cells were cultured in the RPMI1640 medium, supplemented as shown
above. We further added hypoxanthine, aminopterin, and thymidine (HAT; Thermo Fisher Scientific,Inc.), 5% Briclone (NICB, Dublin, Ireland), and 5 μg/mL of plasmocin into the medium. The
hybridoma supernatants were screened by flow cytometry using CHO/mCXCR1 and parental CHOK1. The culture supernatants of hybridomas were filtrated and purified using Ab-Capcher Extra(ProteNova, Kagawa, Japan).
2.4. Flow cytometry
CHO-K1 and CHO/mCXCR1 cells were harvested after brief exposure to 2.5 g/L-Trypsin/ 1
mmol/L-EDTA Solution with Phenol Red (Nacalai Tesque, Inc.). CHO-K1, CHO/mCXCR1, LN229,
and LN229/mCXCR1 cells were washed with 0.1% bovine serum albumin in phosphate-bufferedsaline (PBS) and treated with primary mAbs for 30 min at 4°C. Afterward, cells were treated with
Alexa Fluor 488-conjugated anti-rat IgG (1:1000) or Alexa Fluor 488-conjugated anti-rabbit IgG(1:1000) as well, following the collection of fluorescence data, using an SA3800 Cell Analyzer (SonyCorp., Tokyo, Japan).
2.5. Determination of the binding affinity by flow cytometry
CHO/mCXCR1 and LN229/mCXCR1 were suspended in 100 μL serially diluted anti-mCXCR1
mAbs (25 to 0.006 μg/mL), after which Alexa Fluor 488-conjugated anti-rat IgG (1:200) or Alexa Fluor
488-conjugated anti-rabbit IgG (1:200) were added. Fluorescence data were subsequently collected,using an SA3800 Cell Analyzer (Sony Corp.), following calculation of the dissociation constant (KD)by fitting the binding isotherms into the built-in; one-site binding model in GraphPad PRISM 8(GraphPad Software, Inc., La Jolla, CA).
2.6. Western blot analysis
Cell lysates (10 μg) were boiled in sodium dodecyl sulfate (SDS) sample buffer (Nacalai Tesque,Inc.), after which proteins were separated on 5%–20% polyacrylamide gels (FUJIFILM Wako Pure
Chemical Corporation) and transferred to polyvinylidene difluoride membranes (Merck KGaA).
After blocking with 4% skim milk (Nacalai Tesque, Inc.) in 0.05% Tween 20-containing PBS,
membranes were incubated with 1 μg/mL of Cx1Mab-1, 1 μg/mL of an anti-mouse CXCR1/IL-8RA
mAb (clone 1122A), 1 μg/mL of an anti-DYKDDDDK mAb (clone 1E6), or 1 μg/mL of an anti-β-actinmAb (clone AC-15). Then, they were incubated again with horseradish peroxidase-conjugated antirat immunoglobulins (for Cx1Mab-1; diluted 1:10000; Sigma-Aldrich Corp.), anti-mouse
immunoglobulins (for anti-DYKDDDDK, and anti-β-actin; diluted 1:1000; Agilent Technologies, Inc.,
Santa Clara, CA), or anti-rabbit immunoglobulins (for 1122A; diluted 1:1000; Agilent Technologies,Inc.). Finally, protein bands were detected using ECL Plus Western Blotting Substrate (Thermo Fisher
Scientific, Inc.) or ImmunoStar LD (FUJIFILM Wako Pure Chemical Corporation) with a SayacaImager (DRC Co. Ltd., Tokyo, Japan).
3. Results
3.1. Establishment of anti-mCXCR1 mAbs

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 December 2023

doi:10.20944/preprints202311.0501.v2

4

To develop anti-mCXCR1 mAbs, we employed the CBIS method using mCXCR1-overexpressed
cells. Hybridoma screening was conducted using flow cytometry (Figure 1). A rat was
intraperitoneally immunized with LN229/mCXCR1. Subsequently, hybridomas were seeded into 96well plates, after which flow cytometric analysis was used to extract CHO/mCXCR1-reactive and
CHO-K1-nonreactive supernatants. Afterward, we obtained CHO/mCXCR1-reactive supernatants in
78 of 958 wells (8.1%). We finally established clone Cx1Mab-1 (rat IgG1, kappa) by limiting dilution
and additional screening.

Figure 1. A schematic procedure of anti-mCXCR1 mAbs production. The procedure of Cell-Based
Immunization and Screening (CBIS). LN229/mCXCR1 cells were immunized into an Sprague-Dawley
rat using intraperitoneal injection. The culture supernatants of hybridoma were screened by flow
cytometry. Cx1Mab-1 was established by limiting dilution.

3.2. Flow cytometry
Flow cytometric analysis was conducted using Cx1Mab-1 and another anti-mCXCR1/IL-8RA
mAb (clone 1122A from R&D Systems Inc.) against CHO-K1, CHO/mCXCR1, LN229, and
LN229/mCXCR1. Results showed that Cx1Mab-1 and 1122A recognized CHO/mCXCR1 dosedependently, but not parental CHO-K1 cells (Figure 2). Both mAbs also recognized LN229/mCXCR1
dose-dependently, but not parental LN229 cells (Figure 3). Both Cx1Mab-1 and 1122A reacted with
CHO/mCXCR1 and LN229/mCXCR1 even at 0.01 μg/mL concentration (Figures 2 and 3), indicatingthat both mAbs are highly sensitive.

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 December 2023

doi:10.20944/preprints202311.0501.v2

5

Figure 2. Flow cytometric analysis of anti-mCXCR1 mAbs against CHO/mCXCR1 and CHO-K1.
CHO/mCXCR1 (A) and CHO-K1 cells (B) were treated with 0.01–10 μg/mL of Cx1Mab-1 and 1122A,
followed by treatment with Alexa Fluor 488-conjugated anti-rat IgG and Alexa Fluor 488-conjugatedanti-rabbit IgG, respectively.

Figure 3. Flow cytometric analysis of anti-mCXCR1 mAbs against LN229/mCXCR1 and LN229.
LN229 cells (A), and LN229/mCXCR1 cells (B) were treated with 0.01–10 μg/mL of Cx1Mab-1 and1122A, followed by treatment with Alexa Fluor 488-conjugated anti-rat IgG and Alexa Fluor 488conjugated anti-rabbit IgG, respectively.

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 December 2023

doi:10.20944/preprints202311.0501.v2

6

3.3. Determination of the binding affinity of Cx1Mab-1
The binding affinity of Cx1Mab-1 and 1122A were assessed with CHO/mCXCR1 and
LN229/mCXCR1 using flow cytometry. Results showed that the KD of Cx1Mab-1 for CHO/mCXCR1and LN229/mCXCR1 were 2.6×10-9 M and 2.1×10-8 M, respectively (Figure 4). In contrast, the KD of1122A for CHO/mCXCR1 and LN229/mCXCR1 were 2.7 × 10−9 M and 2.8 × 10−8 M, respectively (Figure4). These results indicate that Cx1Mab-1 possesses a moderate affinity for exogenously overexpressedmCXCR1 in CHO-K1 and LN229 cells.

Figure 4. The determination of the binding affinity of anti-mCXCR1 mAbs. CHO/mCXCR1 (A) or
LN229/mCXCR1 (B) cells were suspended in 100 μL serially diluted Cx1Mab-1 or 1122A (25 to 0.006
μg/mL). Then, cells were treated with Alexa Fluor 488-conjugated anti-rat IgG or Alexa Fluor 488conjugated anti-rabbit IgG. Fluorescence data were subsequently collected using a SA3800 Cell
Analyzer, following the calculation of the dissociation constant (KD) by GraphPad PRISM 8.

3.4. Western blot analysis
Western blot analysis was performed to further assess the availability of Cx1Mab-1. Lysates of
CHO-K1, CHO/mCXCR1, LN229, and LN229/mCXCR1 cells were probed. As demonstrated in Figure
5, Cx1Mab-1 detected the ~48-kDa band of mCXCR1 in lysates from CHO/mCXCR1 and
LN229/mCXCR1 cells, whereas this band was not present in lysates from CHO-K1 and LN229 cells,
indicating that Cx1Mab-1 specifically detects mCXCR1-overexpressed cells.

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 December 2023

doi:10.20944/preprints202311.0501.v2

7

Figure 5. Western blot analysis using anti-mCXCR1 mAbs. Cell lysates of CHO-K1, CHO/mCXCR1,
LN229, and LN229/mCXCR1 cells were electrophoresed and proteins were transferred onto
polyvinylidene difluoride membranes. After blocking, the membranes were incubated with 1 μg/mLof Cx1Mab-1, 1122A, anti-DYKDDDDK (1E6), or anti-β-actin mAb (AC-15), and then incubated withperoxidase-conjugated anti-rat IgG or anti-mouse IgG.

4. Discussion
The TME is composed of various cells including cancer cells, immune cells, and stromal cells[32]. Chemokines and their receptors expressed in these cells modulate a complex TME [23,32].
Neutrophil is one of the major mediators of inflammation. IL-8 secreted from CD4+ T cells recruited
CXCR1/2-expressed neutrophils to the inflammation site [33]. The Neutrophils promoteinflammation by generating reactive oxygen species (ROS) [19,34]. In this study, we established
Cx1Mab-1 which recognizes mCXCR1 with high sensitivity (Figures 2 and 3). Therefore, Cx1Mab-1
would contribute to detecting and isolating the mCXCR1-positive lymphocytes.
Tumor-associated macrophage (TAM) plays a vital role as a tumor immune regulator in TME[35]. TAM produces IL-8 which attenuates cancer immunity by suppressing the infiltration of CD8+

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 December 2023

doi:10.20944/preprints202311.0501.v2

8

T cells and enhances programmed cell death-1 ligand-1 (PD-L1) expression in TAM itself [36].
Blocking IL-8 in TAM by neutralizing antibody suppresses epithelial ovarian cancer migration [37].
Furthermore, CXCR1/2-positive neutrophils and myeloid-derived suppressor cells in cancer patients
also play an important role in immune suppression by obstructing the contact between CD8+ T cells
and the target tumor cells [19]. Therefore, it is interesting to investigate whether Cx1Mab-1 interfereswith the IL-8-CXCR1 interaction. Furthermore, the identification of epitope is essential to know theproperty of Cx1Mab-1.
Therapeutic drugs that target CXCR1/2 have been developed for cancers [12]. SCH527123 is anorally available allosteric inhibitor of CXCR1/2 that can inhibit the neutrophil activity [22,38].
Reparixin selectively blocks CXCR1 which is expressed in human breast cancer stem cells (CSCs) in
preclinical models [39]. Furthermore, reparixin significantly decreases tumor growth in combination
with paclitaxel or docetaxel compared to chemotherapy alone [39,40]. Anti-CXCR1 mAbs also havethe potential to affect CSCs in vitro [39]. Furthermore, the blockers for CXCR1/2 potentiate the efficacy
of immune checkpoint inhibitors (ICIs) through suppression of neutrophils and myeloid-derived
suppressor cells [19,41,42]. Numerous clinical trials demonstrate the promise of combination
therapies treating CXCR1/2-targeted drugs and ICIs [4,43]. We have previously enhanced antibodydependent cellular cytotoxicity (ADCC) activity complement-dependent cytotoxicity (CDC) by
modifying mAb isotypes and defucosylation in mAbs [44–46]. Since Cx1Mab-1 is rat IgG1 which has
no ADCC and CDC activities, it will be converted into a mouse IgG2a version to verify the effect ofdepletion of CXCR1+ immunosuppressive cells in preclinical models.
References
1.
2.
3.
4.
5.
6.
7.
8.

9.

10.

11.

12.
13.

Hughes, C.E.; Nibbs, R.J.B. A guide to chemokines and their receptors. Febs j 2018, 285, 2944-2971,
doi:10.1111/febs.14466.
Nagarsheth, N.; Wicha, M.S.; Zou, W. Chemokines in the cancer microenvironment and their relevance incancer immunotherapy. Nat Rev Immunol 2017, 17, 559-572, doi:10.1038/nri.2017.49.
White, G.E.; Iqbal, A.J.; Greaves, D.R. CC chemokine receptors and chronic inflammation--therapeutic
opportunities and pharmacological challenges. Pharmacol Rev 2013, 65, 47-89, doi:10.1124/pr.111.005074.
Han, Z.J.; Li, Y.B.; Yang, L.X.; Cheng, H.J.; Liu, X.; Chen, H. Roles of the CXCL8-CXCR1/2 Axis in the Tumor
Microenvironment and Immunotherapy. Molecules 2021, 27, doi:10.3390/molecules27010137.
Russo, R.C.; Garcia, C.C.; Teixeira, M.M.; Amaral, F.A. The CXCL8/IL-8 chemokine family and its receptors
in inflammatory diseases. Expert Rev Clin Immunol 2014, 10, 593-619, doi:10.1586/1744666x.2014.894886.
Murphy, P.M.; Tiffany, H.L. Cloning of complementary DNA encoding a functional human interleukin-8
receptor. Science 1991, 253, 1280-1283, doi:10.1126/science.1891716.
Holmes, W.E.; Lee, J.; Kuang, W.J.; Rice, G.C.; Wood, W.I. Structure and functional expression of a humaninterleukin-8 receptor. Science 1991, 253, 1278-1280, doi:10.1126/science.1840701.
Wang, W.; Deng, Z.; Liu, G.; Yang, J.; Zhou, W.; Zhang, C.; Shen, W.; Zhang, Y. Platelet-derived
extracellular vesicles promote the migration and invasion of rheumatoid arthritis fibroblast-likesynoviocytes via CXCR2 signaling. Exp Ther Med 2021, 22, 1120, doi:10.3892/etm.2021.10554.
Bi, H.; Zhang, Y.; Wang, S.; Fang, W.; He, W.; Yin, L.; Xue, Y.; Cheng, Z.; Yang, M.; Shen, J. Interleukin-8
promotes cell migration via CXCR1 and CXCR2 in liver cancer. Oncol Lett 2019, 18, 4176-4184,
doi:10.3892/ol.2019.10735.
Chuntharapai, A.; Lee, J.; Hébert, C.A.; Kim, K.J. Monoclonal antibodies detect different distribution
patterns of IL-8 receptor A and IL-8 receptor B on human peripheral blood leukocytes. J Immunol 1994, 153,
5682-5688.
Tavares, L.P.; Garcia, C.C.; Machado, M.G.; Queiroz-Junior, C.M.; Barthelemy, A.; Trottein, F.; Siqueira,
M.M.; Brandolini, L.; Allegretti, M.; Machado, A.M.; et al. CXCR1/2 Antagonism Is Protective during
Influenza and Post-Influenza Pneumococcal Infection. Front Immunol 2017, 8, 1799,
doi:10.3389/fimmu.2017.01799.
Sitaru, S.; Budke, A.; Bertini, R.; Sperandio, M. Therapeutic inhibition of CXCR1/2: where do we stand?
Intern Emerg Med 2023, 18, 1647-1664, doi:10.1007/s11739-023-03309-5.
Fu, X.; Wang, Q.; Du, H.; Hao, H. CXCL8 and the peritoneal metastasis of ovarian and gastric cancer. Front
Immunol 2023, 14, 1159061, doi:10.3389/fimmu.2023.1159061.

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 December 2023

doi:10.20944/preprints202311.0501.v2

9

14.
15.

16.

17.

18.

19.

20.
21.

22.

23.

24.

25.

26.

27.

28.

29.

30.

Chen, Y.; McAndrews, K.M.; Kalluri, R. Clinical and therapeutic relevance of cancer-associated fibroblasts.
Nat Rev Clin Oncol 2021, 18, 792-804, doi:10.1038/s41571-021-00546-5.
Naito, Y.; Yamamoto, Y.; Sakamoto, N.; Shimomura, I.; Kogure, A.; Kumazaki, M.; Yokoi, A.; Yashiro, M.;
Kiyono, T.; Yanagihara, K.; et al. Cancer extracellular vesicles contribute to stromal heterogeneity by
inducing chemokines in cancer-associated fibroblasts. Oncogene 2019, 38, 5566-5579, doi:10.1038/s41388019-0832-4.
Teijeira, A.; Garasa, S.; Ochoa, M.C.; Villalba, M.; Olivera, I.; Cirella, A.; Eguren-Santamaria, I.; Berraondo,P.; Schalper, K.A.; de Andrea, C.E.; et al. IL8, Neutrophils, and NETs in a Collusion against Cancer
Immunity and Immunotherapy. Clin Cancer Res 2021, 27, 2383-2393, doi:10.1158/1078-0432.Ccr-20-1319.
Schalper, K.A.; Carleton, M.; Zhou, M.; Chen, T.; Feng, Y.; Huang, S.P.; Walsh, A.M.; Baxi, V.; Pandya, D.;
Baradet, T.; et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils andreduced clinical benefit of immune-checkpoint inhibitors. Nat Med 2020, 26, 688-692, doi:10.1038/s41591020-0856-x.
Yuen, K.C.; Liu, L.F.; Gupta, V.; Madireddi, S.; Keerthivasan, S.; Li, C.; Rishipathak, D.; Williams, P.; Kadel,
E.E., 3rd; Koeppen, H.; et al. High systemic and tumor-associated IL-8 correlates with reduced clinicalbenefit of PD-L1 blockade. Nat Med 2020, 26, 693-698, doi:10.1038/s41591-020-0860-1.
Liu, H.; Zhao, Q.; Tan, L.; Wu, X.; Huang, R.; Zuo, Y.; Chen, L.; Yang, J.; Zhang, Z.X.; Ruan, W.; et al.
Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma. Cancer Cell 2023, 41, 693710.e698, doi:10.1016/j.ccell.2023.03.004.
Ruffini, P.A. The CXCL8-CXCR1/2 Axis as a Therapeutic Target in Breast Cancer Stem-Like Cells. Front
Oncol 2019, 9, 40, doi:10.3389/fonc.2019.00040.
Bertini, R.; Allegretti, M.; Bizzarri, C.; Moriconi, A.; Locati, M.; Zampella, G.; Cervellera, M.N.; Di Cioccio,
V.; Cesta, M.C.; Galliera, E.; et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine
receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A 2004, 101, 1179111796, doi:10.1073/pnas.0402090101.
Chapman, R.W.; Minnicozzi, M.; Celly, C.S.; Phillips, J.E.; Kung, T.T.; Hipkin, R.W.; Fan, X.; Rindgen, D.;
Deno, G.; Bond, R.; et al. A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil
recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation.
J Pharmacol Exp Ther 2007, 322, 486-493, doi:10.1124/jpet.106.119040.
Singh, S.; Sadanandam, A.; Nannuru, K.C.; Varney, M.L.; Mayer-Ezell, R.; Bond, R.; Singh, R.K. Smallmolecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cellproliferation, survival, and angiogenesis. Clin Cancer Res 2009, 15, 2380-2386, doi:10.1158/1078-0432.Ccr-082387.
Asano, T.; Nanamiya, R.; Takei, J.; Nakamura, T.; Yanaka, M.; Hosono, H.; Tanaka, T.; Sano, M.; Kaneko,
M.K.; Kato, Y. Development of Anti-Mouse CC Chemokine Receptor 3 Monoclonal Antibodies for Flow
Cytometry. Monoclon Antib Immunodiagn Immunother 2021, 40, 107-112, doi:10.1089/mab.2021.0009.
Tanaka, T.; Nanamiya, R.; Takei, J.; Nakamura, T.; Yanaka, M.; Hosono, H.; Sano, M.; Asano, T.; Kaneko,
M.K.; Kato, Y. Development of Anti-Mouse CC Chemokine Receptor 8 Monoclonal Antibodies for Flow
Cytometry. Monoclon Antib Immunodiagn Immunother 2021, 40, 65-70, doi:10.1089/mab.2021.0005.
Suzuki, H.; Saito, M.; Asano, T.; Tanaka, T.; Kitamura, K.; Kudo, Y.; Kaneko, M.K.; Kato, Y. C(8)Mab-3: An
Anti-Mouse CCR8 Monoclonal Antibody for Immunocytochemistry. Monoclon Antib Immunodiagn
Immunother 2022, 41, 110-114, doi:10.1089/mab.2022.0002.
Saito, M.; Suzuki, H.; Tanaka, T.; Asano, T.; Kaneko, M.K.; Kato, Y. Development of an Anti-Mouse CCR8
Monoclonal Antibody (C(8)Mab-1) for Flow Cytometry and Immunocytochemistry. Monoclon AntibImmunodiagn Immunother 2022, 41, 333-338, doi:10.1089/mab.2021.0069.
Nanamiya, R.; Takei, J.; Asano, T.; Tanaka, T.; Sano, M.; Nakamura, T.; Yanaka, M.; Hosono, H.; Kaneko,
M.K.; Kato, Y. Development of Anti-Human CC Chemokine Receptor 9 Monoclonal Antibodies for Flow
Cytometry. Monoclon Antib Immunodiagn Immunother 2021, 40, 101-106, doi:10.1089/mab.2021.0007.
Ouchida, T.; Isoda, Y.; Tanaka, T.; Kaneko, M.K.; Suzuki, H.; Kato, Y. Cx<sub>3</sub>Mab-4: a Novel Antimouse
CXCR3
Monoclonal
Antibodyfor
Flow
Cytometry.
Preprints2023,
doi:10.20944/preprints202311.0805.v1.
Ouchida, T.S., H.; Tanaka, T.; Kaneko, M.K.; Kato, Y. Cx4Mab-1: a Novel Anti-mouse CXCR4 Monoclonal
Antibody for Flow Cytometry. Preprints 2023 2023, 2023110501, doi:10.20944/preprints202311.0501.v1.

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 December 2023

doi:10.20944/preprints202311.0501.v2

10

31.

32.
33.

34.

35.

36.

37.

38.

39.

40.

41.

42.

43.

44.

45.

46.

Kitamura, K.; Suzuki, H.; Kaneko, M.K.; Kato, Y. Cx(6)Mab-1: A Novel Anti-Mouse CXCR6 Monoclonal
Antibody Established by N-Terminal Peptide Immunization. Monoclon Antib Immunodiagn Immunother2022, 41, 133-141, doi:10.1089/mab.2022.0010.
Borlongan, M.C.; Saha, D.; Wang, H. Tumor Microenvironment: A Niche for Cancer Stem Cell
Immunotherapy. Stem Cell Rev Rep 2023, doi:10.1007/s12015-023-10639-6.
Hammond, M.E.; Lapointe, G.R.; Feucht, P.H.; Hilt, S.; Gallegos, C.A.; Gordon, C.A.; Giedlin, M.A.;
Mullenbach, G.; Tekamp-Olson, P. IL-8 induces neutrophil chemotaxis predominantly via type I IL-8
receptors. J Immunol 1995, 155, 1428-1433.
Thai, T.D.; Chuenchom, C.; Donsa, W.; Faksri, K.; Sripa, B.; Edwards, S.W.; Salao, K. Helicobacter pylori
extract induces purified neutrophils to produce reactive oxygen species only in the presence of plasma.
Biomed Rep 2023, 19, 89, doi:10.3892/br.2023.1671.
Qin, R.; Ren, W.; Ya, G.; Wang, B.; He, J.; Ren, S.; Jiang, L.; Zhao, S. Role of chemokines in the crosstalk
between tumor and tumor-associated macrophages. Clin Exp Med 2023, 23, 1359-1373, doi:10.1007/s10238022-00888-z.
Lin, C.; He, H.; Liu, H.; Li, R.; Chen, Y.; Qi, Y.; Jiang, Q.; Chen, L.; Zhang, P.; Zhang, H.; et al. Tumourassociated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1
expression in gastric cancer. Gut 2019, 68, 1764-1773, doi:10.1136/gutjnl-2018-316324.
Zhang, T.; Ma, Z.; Wang, R.; Wang, Y.; Wang, S.; Cheng, Z.; Xu, H.; Jin, X.; Li, W.; Wang, X. Thrombin
facilitates invasion of ovarian cancer along peritoneum by inducing monocyte differentiation toward
tumor-associated macrophage-like cells. Cancer Immunol Immunother 2010, 59, 1097-1108,
doi:10.1007/s00262-010-0836-y.
Gonsiorek, W.; Fan, X.; Hesk, D.; Fossetta, J.; Qiu, H.; Jakway, J.; Billah, M.; Dwyer, M.; Chao, J.; Deno, G.;
et al. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist. J
Pharmacol Exp Ther 2007, 322, 477-485, doi:10.1124/jpet.106.118927.
Ginestier, C.; Liu, S.; Diebel, M.E.; Korkaya, H.; Luo, M.; Brown, M.; Wicinski, J.; Cabaud, O.; CharafeJauffret, E.; Birnbaum, D.; et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro
and in xenografts. J Clin Invest 2010, 120, 485-497, doi:10.1172/jci39397.
Brandolini, L.; Cristiano, L.; Fidoamore, A.; De Pizzol, M.; Di Giacomo, E.; Florio, T.M.; Confalone, G.;
Galante, A.; Cinque, B.; Benedetti, E.; et al. Targeting CXCR1 on breast cancer stem cells: signaling
pathways and clinical application modelling. Oncotarget 2015, 6, 43375-43394, doi:10.18632/oncotarget.6234.
Gulhati, P.; Schalck, A.; Jiang, S.; Shang, X.; Wu, C.J.; Hou, P.; Ruiz, S.H.; Soto, L.S.; Parra, E.; Ying, H.; etal. Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor
immunity and durable response in pancreatic cancer. Nat Cancer 2023, 4, 62-80, doi:10.1038/s43018-02200500-z.
Teijeira, Á.; Garasa, S.; Gato, M.; Alfaro, C.; Migueliz, I.; Cirella, A.; de Andrea, C.; Ochoa, M.C.; Otano, I.;
Etxeberria, I.; et al. CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce
Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity. Immunity 2020, 52, 856-871.e858,
doi:10.1016/j.immuni.2020.03.001.
Kargl, J.; Zhu, X.; Zhang, H.; Yang, G.H.Y.; Friesen, T.J.; Shipley, M.; Maeda, D.Y.; Zebala, J.A.; McKayFleisch, J.; Meredith, G.; et al. Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment
failure in NSCLC. JCI Insight 2019, 4, doi:10.1172/jci.insight.130850.
Li, G.; Suzuki, H.; Ohishi, T.; Asano, T.; Tanaka, T.; Yanaka, M.; Nakamura, T.; Yoshikawa, T.; Kawada, M.;
Kaneko, M.K.; et al. Antitumor activities of a defucosylated anti-EpCAM monoclonal antibody in colorectal
carcinoma xenograft models. Int J Mol Med 2023, 51, doi:10.3892/ijmm.2023.5221.
Tateyama, N.; Nanamiya, R.; Ohishi, T.; Takei, J.; Nakamura, T.; Yanaka, M.; Hosono, H.; Saito, M.; Asano,T.; Tanaka, T.; et al. Defucosylated Anti-Epidermal Growth Factor Receptor Monoclonal Antibody 134mG(2a)-f Exerts Antitumor Activities in Mouse Xenograft Models of Dog Epidermal Growth Factor
Receptor-Overexpressed Cells. Monoclon Antib Immunodiagn Immunother 2021, 40, 177-183,
doi:10.1089/mab.2021.0022.
Tanaka, T.; Suzuki, H.; Ohishi, T.; Kaneko, M.K.; Kato, Y. Antitumor activities against breast cancers by anafucosylated anti-HER2 monoclonal antibody H(2) Mab-77-mG(2a) -f. Cancer Sci 2023,
doi:10.1111/cas.16008.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely thoseof the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s)Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 December 2023

doi:10.20944/preprints202311.0501.v2

11

disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or
products referred to in the content.